A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Progressive Supranuclear Palsy and Corticobasal Degeneration, sponsored by Avid Radiopharmaceuticals. Completed at 5 sites in United States. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-28.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 31st largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2014, is one of 19 in phase 1, and was the 21st registered.
171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.
Browse Supranuclear Palsy, Progressive studies →19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
Adam Boxer · Sites in United States
Ages 41–86
Novartis Pharmaceuticals · Sites in United States, Australia, Belgium and 9 more countries
Ages 41–81
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
University of Pennsylvania · Sites in United States
Ages 40–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 18 · Phase 3 5 · Phase 4 2
First in 1995; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 43 across 102 interventional studies indexed under Supranuclear Palsy, Progressive.
Median enrollment 43 across the 52 interventional studies, 200 across the 31 observational. Of the 54 that completed or were terminated, 9 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 84 have an industry lead sponsor. The 10 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
Eli Lilly and Company has 1 study filed under Supranuclear Palsy, Progressive — fewer than ten, so there is no comparison to draw.
8 of the studies in Supranuclear Palsy, Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03872102University of Texas Southwestern Medical CenterFacilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging | 2026-12-31 |
| NCT05913687University of FloridaAutomated Imaging Differentiation of Parkinsonism | 2027-03-31 |
| NCT04468932Oregon Health and Science UniversityTranscranial Magnetic Stimulation in Progressive Supranuclear Palsy | 2027-04 |
| NCT07863180Prabesh KanelTributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | 2027-05 |
| NCT05459753University of MichiganCholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cognitively Healthy Volunteers
CBD and PSP subjects
PSP subjects only
CBD subjects only
Exclusion Criteria:
All subjects
PSP and CBD subjects
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Healthy volunteers receiving a flortaucipir PET scan at baseline.
Drug: Flortaucipir F18 · Procedure: Brain PET scan
IV injection, 370 megabecquerel (MBq) (10 mCi)
Also known as: [F18]T807, 18F-AV-1451, LY3191748, Tauvid
positron emission tomography (PET) scan of the brain 75-105 minutes post-injection
Flortaucipir Imaging in PSP, CBD and Healthy Volunteers
A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline and 9 month scans
Subjects recruited between Aug 2014 and Jul 2016.
| Milestone | PSP Subjects | CBD Subjects | Healthy Volunteers |
|---|---|---|---|
| Started | 20 | 6 | 3 |
| Completed | 18 | 5 | 3 |
| Not completed | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 |
A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | PSP Subjects | CBD Subjects | Healthy Volunteers | All Subjects |
|---|---|---|---|---|
| Right Dentate Baseline | 1.17 ± 0.12 | 1.12 ± 0.04 | 1.03 ± 0.12 | 1.15 ± 0.12 |
| Right Dentate 9 months | 1.17 ± 0.11 | 1.11 ± 0.05 | — | 1.15 ± 0.10 |
| Left Dentate Baseline | 1.16 ± 0.10 | 1.09 ± 0.04 | 1.08 ± 0.07 | 1.14 ± 0.09 |
| Left Dentate 9 months | 1.13 ± 0.11 | 1.08 ± 0.05 | — | 1.12 ± 0.10 |
| Right Globus Pallidus Baseline | 1.60 ± 0.15 | 1.40 ± 0.20 | 1.29 ± 0.06 | 1.53 ± 0.19 |
| Right Globus Pallidus 9 Months | 1.58 ± 0.13 | 1.47 ± 0.19 | — | 1.55 ± 0.15 |
| Left Globus Pallidus Baseline | 1.62 ± 0.15 | 1.56 ± 0.32 | 1.30 ± 0.07 | 1.58 ± 0.21 |
| Left Globus Pallidus 9 Months | 1.62 ± 0.15 | 1.62 ± 0.40 | — | 1.62 ± 0.21 |
| Global PSP/CBD Summary Baseline | 1.38 ± 0.10 | 1.29 ± 0.11 | 1.17 ± 0.03 | 1.34 ± 0.12 |
| Global PSP/CBD Summary 9 Months | 1.37 ± 0.09 | 1.32 ± 0.13 | — | 1.36 ± 0.10 |
| AD Cortical Baseline | 0.99 ± 0.03 | 0.99 ± 0.06 | 1.02 ± 0.02 | 0.99 ± 0.04 |
| AD Cortical 9 Months | 0.99 ± 0.03 | 1.00 ± 0.05 | — | 0.99 ± 0.04 |
Collected over End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.. Non-serious events are listed at a 1.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PSP Subjects | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| CBD Subjects | 1/6 (16.7%) | 0/6 (0%) | 1/6 (16.7%) |
| Healthy Volunteers | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Event | PSP Subjects | CBD Subjects | Healthy Volunteers |
|---|---|---|---|
| muscle spasmsMusculoskeletal and connective tissue disorders | 0/20 | 1/6 | 0/3 |
| bronchial secretion retentionRespiratory, thoracic and mediastinal disorders | 1/20 | 0/6 | 0/3 |
| astheniaGeneral disorders | 1/20 | 0/6 | 0/3 |
| Age, Continuous(years) | PSP Subjects | CBD Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| Mean | 69.2 ± 5.88 | 72.2 ± 7.41 | 68.7 ± 10.41 | 69.8 ± 6.53 |
| Sex: Female, Male(Participants) | PSP Subjects | CBD Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| Female | 6 | 4 | 0 | 10 |
| Male | 14 | 2 | 3 | 19 |
| Ethnicity (NIH/OMB)(Participants) | PSP Subjects | CBD Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 19 | 6 | 3 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PSP Subjects | CBD Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 18 | 6 | 3 | 27 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Region of Enrollment(Participants) | PSP Subjects | CBD Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| United States | 20 | 6 | 3 | 29 |
| Mini Mental Status Exam (MMSE)(units on a scale) | PSP Subjects | CBD Subjects | Healthy Volunteers | Total |
|---|---|---|---|---|
| Mean | 26.5 ± 3.12 | 26.3 ± 4.32 | 29.3 ± 0.58 | 26.7 ± 3.28 |
Ran from Aug 2014 to primary completion in Jul 2016, 22 months.
Results were first posted in Aug 2020, 4 years 1 month after primary completion.
Of 15 phase 1 interventional studies under Supranuclear Palsy, Progressive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 23. This study's 22 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir
Supranuclear Palsy, Progressive →